GlassScriptPhysician profile
Lori A Cappello
NPI 1164076840
$3,247.68
in general payments reported to CMS, 2019-2025
27 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $260 · 2023: $608 · 2024: $454 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,418.09 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,723.73 | 2021-2025 | Optune, Optune Gio |
| Telix Pharmaceuticals | $183.74 | 2025 | Illuccix |
| Novartis Pharmaceuticals Corporation | $152.65 | 2025 | |
| Janssen Biotech, INC. | $146.95 | 2023-2025 | Rybrevant, Erleada |
| Daiichi Sankyo INC. | $132.51 | 2021 | |
| Abbvie INC. | $98.65 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $95.67 | 2023-2025 | Tagrisso, Evusheld, Imfinzi |
| Merck Sharp & Dohme LLC | $94.89 | 2024-2025 | Keytruda, Lynparza |
| Incyte Corporation | $76.97 | 2025 | Jakafi |
| Eisai INC. | $76.18 | 2025 | |
| Taiho Oncology, INC. | $51.87 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $51.06 | 2025 | Pyrukynd |
| Genzyme Corporation | $42.01 | 2025 | |
| Emd Serono, INC. | $37.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $36.69 | 2024-2025 | Libtayo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $36.07 | 2025 | |
| Pharmaessentia USA Corporation | $32.56 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $24.12 | 2025 | |
| Beone Medicines USA, INC. | $20.57 | 2025 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $20.32 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.99 | 2025 | Monoferric |
| Janssen Scientific Affairs, LLC | $17.82 | 2024 | Erleada |
| Genentech USA, INC. | $17.77 | 2024 | Tecentriq, Alecensa |
| Blue Earth Diagnostics | $15.30 | 2024 | |
| Apellis Pharmaceuticals, INC. | $15.20 | 2024 | Empaveli |
| Kyowa Kirin, INC. | $14.29 | 2021 | |
| Allergan, INC. | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Cappello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.